Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Panitumumab|DRUG: Nab-paclitaxel|DRUG: Carboplatin|DRUG: 5-Fluorouracil|DRUG: Epirubicin|DRUG: Cyclophosphamide
Sponsor: M.D. Anderson Cancer Center
Collaborators: Celgene Corporation|Amgen